Coverage
-
February 22, 2021
The Patent Trial and Appeal Board said it won't review six Allergan patents covering the company's injectable skin filler Juvederm, despite expressing skepticism toward them, after Allergan announced it has inked a licensing agreement with the low-cost rival challenging the patents.
1 other articles on this case.
View all »